Vabysmo 120 mg/mL solution for injection, Eylea 40 mg/mL solution for injection in pre-filled syringe clinical trials

Faricimab for high-frequent Aflibercept treated Neovascular age-related macular degeneration: a monocenter, randomized, double-masked comparator-controlled study (FAN study)

This study compares two treatments, Vabysmo and Eylea, for a serious eye condition called 'wet' age-related macular degeneration (AMD). The aim is to see which treatment can keep the eye healthy and vision stable for longer, with fewer injections.